BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kessing LV, González-Pinto A, Fagiolini A, Bechdolf A, Reif A, Yildiz A, Etain B, Henry C, Severus E, Reininghaus EZ, Morken G, Goodwin GM, Scott J, Geddes JR, Rietschel M, Landén M, Manchia M, Bauer M, Martinez-Cengotitabengoa M, Andreassen OA, Ritter P, Kupka R, Licht RW, Nielsen RE, Schulze TG, Hajek T, Lagerberg TV, Bergink V, Vieta E. DSM-5 and ICD-11 criteria for bipolar disorder: Implications for the prevalence of bipolar disorder and validity of the diagnosis - A narrative review from the ECNP bipolar disorders network. Eur Neuropsychopharmacol 2021;47:54-61. [PMID: 33541809 DOI: 10.1016/j.euroneuro.2021.01.097] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Ghaemi SN, Angst J, Vohringer PA, Youngstrom EA, Phelps J, Mitchell PB, McIntyre RS, Bauer M, Vieta E, Gershon S. Clinical research diagnostic criteria for bipolar illness (CRDC-BP): rationale and validity. Int J Bipolar Disord 2022;10:23. [PMID: 36227452 DOI: 10.1186/s40345-022-00267-3] [Reference Citation Analysis]
2 Post RM, Leverich GS, Mcelroy SL, Kupka R, Suppes T, Altshuler LL, Nolen WA, Frye MA, Keck PE, Grunze H, Rowe M. Are personality disorders in bipolar patients more frequent in the US than Europe? European Neuropsychopharmacology 2022;58:47-54. [DOI: 10.1016/j.euroneuro.2022.02.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sparacino G, Verdolini N, Vieta E, Pacchiarotti I. Existing and emerging pharmacological approaches to the treatment of mania: A critical overview. Transl Psychiatry 2022;12. [DOI: 10.1038/s41398-022-01928-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Faurholt-Jepsen M, Rohani DA, Busk J, Vinberg M, Bardram JE, Kessing LV. Voice analyses using smartphone-based data in patients with bipolar disorder, unaffected relatives and healthy control individuals, and during different affective states. Int J Bipolar Disord 2021;9:38. [PMID: 34850296 DOI: 10.1186/s40345-021-00243-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Yoldi-Negrete M, Fresán-Orellana A, Jiménez-Tirado M, Martínez-Camarillo S, Palacios-Cruz L, Vieta E, Ortega-Ortiz H, Becerra-Palars C, Gutiérrez-Mora D, Camarena Medellín B. Ten-year course of treated bipolar I disorder: The role of polarity at onset. Brain Behav 2021;11:e2279. [PMID: 34626089 DOI: 10.1002/brb3.2279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kamali M, Pegg S, Janos JA, Bobo WV, Brody B, Gao K, Ketter TA, McElroy SL, McInnis MG, Rabideau DJ, Reilly-Harrington NA, Shelton RC, Sylvia LG, Tohen M, Nierenberg A. Illness stage and predominant polarity in bipolar disorder: Correlation with burden of illness and moderation of treatment outcome. J Psychiatr Res 2021;140:205-13. [PMID: 34118638 DOI: 10.1016/j.jpsychires.2021.05.082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Vieta E, Angst J. Bipolar disorder cohort studies: Crucial, but underfunded. European Neuropsychopharmacology 2021;47:31-3. [DOI: 10.1016/j.euroneuro.2021.03.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 15.0] [Reference Citation Analysis]
8 Carta MG, Colom F, Erfurth A, Fornaro M, Grunze H, Hantouche E, Nardi AE, Preti A, Vieta E, Karam E. In Memory of Hagop Akiskal. Clin Pract Epidemiol Ment Health 2021;17:48-51. [PMID: 34249138 DOI: 10.2174/1745017902117010048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Pacchiarotti I, Verdolini N. Antidepressants in Bipolar II Depression: Yes and no. Eur Neuropsychopharmacol 2021;47:48-50. [PMID: 33990029 DOI: 10.1016/j.euroneuro.2021.04.009] [Reference Citation Analysis]